The COVID-19 drug that has been researched by University of Airlangga Surabaya is being evaluated by the Food and Drug Administration of the Republic of Indonesia.
The evaluation carried out by the Food and Drug Supervisory Agency of the Republic of Indonesia was a refinement of questions regarding five drug combinations from University of Airlangga Surabaya
The Food and Drug Administration has not asked the University of Airlangga Surabaya to conduct a clinical trial and is still conducting a review and waiting for the final results
The five combinations of COVID-19 drugs are lopinavir-ritonavir-azithromycin, lopinavir-ritonavir-doxycycline, lopinavir-ritonavir-clarithromycin, hydroxychloroquine-azithromycin, and hydroxychloroquine-doxycycline.
